 |
|
Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L. Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim
Clin Mol Hepatol. 2022;28(3):497-509. Published online 2022 Apr 28 DOI: https://doi.org/10.3350/cmh.2022.0019
|
|
Citations to this article as recorded by
 New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao-Dong Qin, Xiao-Dong Jiao, Ke Liu, Zhan Wang, Yuan-Sheng Zang
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef Ticagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease
Eun Jeoung Lee, Seung Min Lee, Ju Hee Oh, Hye Young Kim, Waqar Khalid Saeed, Hyun Sung Kim, Dae Won Jun
Nutrients.2024; 16(7): 920. CrossRef From NAFLD to HCC: Advances in noninvasive diagnosis
Qinchen Xu, Maoxiao Feng, Yidan Ren, Xiaoyan Liu, Huiru Gao, Zigan Li, Xin Su, Qin Wang, Yunshan Wang
Biomedicine & Pharmacotherapy.2023; 165: 115028. CrossRef Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials
Joel Yeh Siang Chen, Damien Chua, Carissa Odelia Lim, Wan Xi Ho, Nguan Soon Tan
International Journal of Molecular Sciences.2022; 24(1): 158. CrossRef
|